Giltetir
Second-generation, oral, highly selective tyrosine kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia who have FLT3 mutation.
Therapeutic Area
Onco-Hematology
Active Ingredient
Gilteritinib
Line
Hematology + Oncology
Presentation:
40 mg x 90 coated tablets
